For research and educational purposes only. Not intended for human consumption.
GLP2-T
Extensively Studied- •SUMMIT trial: 38% reduced CV death/HF
- •HR 0.62 for worsening heart failure
- •Heart failure with preserved EF indication
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
What is GLP2-T?
GLP2-T is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. The 2024 SUMMIT trial showed 38% reduction in cardiovascular death or worsening heart failure (HR 0.62).
Key Benefits
Dramatic weight loss (15-22% body weight), superior diabetes control, reduced cardiovascular risk (HR 0.62 for CV death/HF worsening in SUMMIT), improved insulin sensitivity, appetite suppression, preserved muscle mass.
Mechanism of Action
Dual agonist of GIP and GLP-1 receptors, glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, central satiety signaling through hypothalamic pathways.
Molecular Information
Pharmacokinetics
Research Indications
Severe Obesity Management
Clinical trials demonstrate 15-22% body weight reduction - superior to all existing weight loss medications including glp1-s.
Metabolic Syndrome Reversal
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance.
Body Composition Optimization
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with exercise.
Research Protocols
Disclaimer: GLP2-T is FDA-approved. These protocols reflect clinical trial guidelines. Always consult a healthcare provider before use. Dose titration is required to minimize side effects.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight loss initiation | 2.5mg weekly | Once weekly | SubQ injection |
| Weight loss progression | 5mg weekly | Once weekly | SubQ injection |
| Weight loss optimization | 7.5-10mg weekly | Once weekly | SubQ injection |
| Maximum weight loss | 12.5-15mg weekly | Once weekly | SubQ injection |
| Diabetes management | 5-15mg weekly | Once weekly | SubQ injection |
Timing: GLP2-T can be injected at any time of day, with or without food. Choose a consistent day of the week for weekly injections to maintain steady levels.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigerator and allow to reach room temperature for 15-20 minutes
Clean vial tops with alcohol wipes
Calculate appropriate reconstitution volume based on desired concentration
Draw calculated amount of bacteriostatic water into insulin syringe
Insert needle into vial at 45-degree angle against glass wall, NOT directly into powder
Slowly inject BAC water down the side of the vial
Gently swirl vial in circular motion - NEVER shake vigorously
Final solution should be completely clear and colorless
Label vial with reconstitution date and concentration
Store in refrigerator at 2-8°C immediately, use within 28 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White to Off-White Lyophilized Powder
Properly freeze-dried glp2-t appears as light, fluffy powder cake without clumping.
Clear Reconstituted Solution
Should be completely clear and colorless after proper reconstitution.
Intact Vial Seal and Proper Labeling
Rubber stopper should be intact with clear dosage labeling.
Clumping, Discoloration, or Moisture
Powder should not be clumped, yellow/brown colored, or show signs of moisture damage.
Persistent Cloudiness After Reconstitution
Cloudiness indicates protein aggregation or contamination.
What to Expect
- •Appetite reduction within 1-3 days of first injection
- •Mild to moderate nausea for first 2-4 weeks (typically improves)
- •1-3 lbs weight loss per week during active weight loss phase
- •Improved blood sugar control within 1-2 weeks for diabetics
- •Dramatically reduced food cravings and smaller portion satisfaction
- •Peak weight loss effects typically seen at 16-24 weeks
- •Improved energy levels after initial adaptation period
Side Effects & Safety
Side Effects
- •Start with lowest dose (2.5mg) and escalate gradually every 4 weeks
- •Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2
- •Monitor for signs of acute pancreatitis
- •Significant nausea is common initially - stay hydrated and eat smaller meals
- •Requires prescription and medical supervision
- •Store in refrigerator between 2-8°C, never freeze
- •May require adjustment of other diabetes medications
When to Stop
- •Severe or persistent nausea/vomiting
- •Signs of pancreatitis (severe abdominal pain)
- •Allergic reactions
- •Severe hypoglycemia
- •Changes in vision
- •Kidney problems
- •Consult healthcare provider immediately
References
4 StudiesSUMMIT Heart Failure Trial (2024)
731 HFpEF patients | 104-week median follow-up | CV death/HF worsening: HR 0.62
GLP2-T reduced primary endpoint (CV death or worsening heart failure) from 15.3% to 9.9% (HR 0.62, p=0.026), plus improved 6-minute walk distance (+26m vs +10m), hsCRP (-38.8%), and KCCQ-CSS (+19.5 vs +12.7).
SELECT Cardiovascular Outcomes
12,785 T2DM patients | 3.5-year follow-up | Primary prevention study
26% reduction in major adverse cardiovascular events, establishing cardioprotective benefits.
SURMOUNT-1 Phase 3 Trial
2,539 adults with obesity | 72-week study | Multiple dose levels
15mg weekly dose achieved 22.5% weight loss vs 2.4% placebo - largest weight loss seen in pharmaceutical trials.
Quick Start Guide
Research Disclaimer
GLP2-T is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving GLP2-T must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of GLP2-T for any purpose. Consult qualified professionals for any research applications.